New Method Aims to Improve ALS Clinical Trial Results
A new stratification approach for ALS clinical trials aims to better capture the effect of potential new treatments.
Updated on Oct. 28, 2026 in Alzheimer’s
Live Poll
Do you believe new research methods are successfully accelerating the development of treatments for neurodegenerative diseases?
Coya Therapeutics has introduced a new method for stratifying ALS clinical trial participants based on their baseline levels of neurofilament light chain. This approach aims to address the disease progression variability often seen in studies of this condition, which impacts approximately 120 trial participants.
Why it matters
By grouping subjects into low, medium, and high tiers, researchers hope to improve the clarity of study results by accounting for biological heterogeneity. This shift could help clarify whether new treatments like COYA 302 are truly effective by reducing noise in data measuring patient function.
The proposed stratification methodology uses baseline serum neurofilament light chain levels, a protein marker of neuronal damage, to group 120 subjects in the ongoing ALSTARS trial. It is currently unknown if this stratification will statistically improve results for the primary outcome measure, the ALSFRS-R.
The players
Coya Therapeutics
A Houston-based biotechnology company focused on developing therapies for neurodegenerative diseases including ALS.
The details
Neurofilament light chain is a structural protein that leaks into the blood and cerebrospinal fluid as neurons deteriorate. By measuring this marker at the start of a study, investigators can better balance the severity of disease across treatment arms. This helps ensure that a study’s observed effects are linked to the drug, COYA 302, rather than the initial, naturally varying speed of neuronal loss among patients.
Timeline
October 28, 2026: Coya Therapeutics presented the new stratification methodology at the NEALS meeting in Clearwater, Florida.
Health Landscape
Clinical trials for ALS have historically struggled with the high variability of the disease, which is 90% sporadic in nature. This new stratification approach attempts to stabilize trial data relative to the ALS Functional Rating Scale-Revised, the primary tool for measuring patient function.
While this methodology applies to clinical trial design, it highlights the importance of biomarker tracking in understanding neurodegenerative disease. If you are participating in clinical research, consider discussing with your physician how specific baseline biomarkers may influence your trial results.
The takeaway
Advancements in patient stratification help ensure that clinical trials provide more accurate insights into whether a medication works. Patients and families navigating ALS should speak with their care team about whether clinical trials or specific biomarker tests are appropriate for their situation.
What happens next
Patients enrolled in the 48-week ALSTARS trial are expected to be eligible for an open-label extension upon completion of the study.
Further reading
Learn more about ongoing research into Alzheimer’s for broader context on neurodegenerative disease studies.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new research methods are successfully accelerating the development of treatments for neurodegenerative diseases?
